Article
Oncology
Chia-Ing Jan, Shi-Wei Huang, Peter Canoll, Jeffrey N. Bruce, Yu-Chuan Lin, Chih-Ming Pan, Hsin-Man Lu, Shao-Chih Chiu, Der-Yang Cho
Summary: The study introduces a novel CAR-NK strategy targeting HLA-G in solid tumors, which shows effective cytolytic action in vitro and in vivo. Combination therapy with low-dose chemotherapy enhances tumor ablation, suggesting a potential wide applicability in treating solid tumors.
JOURNAL FOR IMMUNOTHERAPY OF CANCER
(2021)
Review
Oncology
Yasuyuki Matsumoto, Tongzhong Ju
Summary: Glycosylation is a pivotal post-translational modification that plays important roles in various biological processes. In cancers, altered glycosylation known as TACAs has been found to facilitate tumor formation, progression, and metastasis. Recent studies also reveal novel roles of TACAs in modulating the tumor microenvironment. TACAs can serve as potential tumor biomarkers, glycoimmune checkpoints, and therapeutics. This review summarizes the established and promising immunotherapy-targeting TACAs, including monoclonal antibody therapy, CART therapy, and vaccination.
Review
Chemistry, Multidisciplinary
Jiao-jiao Ni, Zi-zhen Zhang, Ming-jie Ge, Jing-yu Chen, Wei Zhuo
Summary: As a breakthrough strategy for cancer treatment, immunotherapy stimulates the immune system to fight cancer, providing a durable antitumor response. Due to the low response rate and unique toxicity profiles of immunotherapy, combining it with other therapies has gained attention. Immune-based combination therapy has achieved promising results in clinical trials, with FDA approval for certain cancers.
ACTA PHARMACOLOGICA SINICA
(2023)
Review
Pharmacology & Pharmacy
Claire O. Kisamore, Brittany D. Elliott, A. Courtney Devries, Randy J. Nelson, William H. Walker II
Summary: Circadian rhythms are internal manifestations of the 24-h solar day that synchronize biological and behavioral processes to improve adaptive function and survival. Chronotherapy optimizes drug administration based on circadian rhythms to achieve maximum therapeutic efficacy and minimize side effects. This review examines the evidence for chronotherapeutic treatment for solid tumors, including chrono-chemotherapy, chrono-radiotherapy, and alternative chronotherapeutics, and discusses areas for further research and challenges in the field.
Article
Oncology
Joshua R. Faust, Darcy Hamill, Edward Anders Kolb, Anilkumar Gopalakrishnapillai, Sonali P. Barwe
Summary: This review summarizes the function of mesothelin, its role in cancer, and opportunities for targeted immunotherapy. Current research focuses on designing targeted cancer therapies utilizing mesothelin, including various immunotherapeutic methods. Studies highlight the potential impact of this approach as a unique opportunity to treat hard-to-cure acute myeloid leukemia.
Article
Chemistry, Multidisciplinary
Jia-Xin An, Zi-Yi Han, You-Teng Qin, Chu-Xin Li, Jin-Lian He, Xian-Zheng Zhang
Summary: This study reports a strategy of attaching bacteria to macrophages, which sustainably stimulates the polarization of macrophages and reduces tumor progression in an immunosuppressive tumor microenvironment without any side effects. This research opens a new avenue for the development of cell therapies.
ADVANCED MATERIALS
(2023)
Article
Medicine, Research & Experimental
Yi Luan, Mingli Li, Yi Zhao, Qianqian Li, Jia Wen, Siqi Gao, Yang Yang
Summary: ***
The centrosome is a special organelle in human cells, with abnormalities potentially promoting cancer progression by affecting processes like mitosis and cell migration. Further research into the impact of centrosome abnormalities on tumors may help identify new therapeutic strategies.
BIOMEDICINE & PHARMACOTHERAPY
(2021)
Review
Oncology
Diana C. Simao, Kevin K. Zarrabi, Jose L. Mendes, Ricardo Luz, Jorge A. Garcia, William K. Kelly, Pedro C. Barata
Summary: Cancer treatments have changed with the introduction of immunotherapy, and new agents that redirect T-cells against cancer are rapidly emerging in multiple tumor types. However, the development of immunotherapy strategies remains a challenge in prostate cancer due to its heterogeneous and immune-suppressive tumor microenvironment.
Review
Biochemistry & Molecular Biology
Limei Yin, Zhengwei Wan, Ping Sun, Ping Shuai, Yuping Liu
Summary: CAR-T cell therapy has been successful in treating hematological malignancies, but it has limited efficacy in solid tumors as a monotherapy. Complementary therapeutics are needed to improve the response of CAR-T cell monotherapy in solid tumors. Further data, particularly from multicenter clinical trials, are required before CAR-T combination therapy can be used in clinical settings.
BIOCHIMICA ET BIOPHYSICA ACTA-REVIEWS ON CANCER
(2023)
Review
Oncology
Paz J. Vellanki, Soma Ghosh, Anand Pathak, Michael J. Fusco, Erik W. Bloomquist, Shenghui Tang, Harpreet Singh, Reena Philip, Richard Pazdur, Julia A. Beaver
Summary: In the era of precision oncology, the use of circulating tumor DNA (ctDNA) is becoming increasingly important for the diagnosis and management of cancer patients. ctDNA-based assays have been approved for targeted therapies and are also being developed for use with immuno-oncology-based therapies. For early-stage solid tumor cancers, ctDNA can be crucial for detecting molecular residual disease (MRD) and guiding treatment decisions. Clinical trials are also utilizing ctDNA for patient selection and stratification in order to improve trial efficiency. However, standardization and further validation are needed before ctDNA can be considered as an efficacy-response biomarker for regulatory decision making.
JOURNAL FOR IMMUNOTHERAPY OF CANCER
(2023)
Article
Oncology
Ahmad A. Tarhini, Jennifer R. Eads, Kathleen N. Moore, Valerie Tatard-Leitman, John Wright, Patrick M. Forde, Robert L. Ferris
Summary: The management of locoregionally advanced solid tumors is challenging and typically involves a combination of surgery, radiotherapy, and systemic therapy. Preoperative neoadjuvant systemic therapy, particularly with immunotherapeutic agents, has the potential to improve clinical outcomes. Progress has been made in neoadjuvant immunotherapy for locoregionally advanced resectable solid tumors, leading to ongoing trials and changes in clinical practice. Pathological responses and biospecimens obtained during neoadjuvant studies can guide treatment decisions and future drug development.
JOURNAL FOR IMMUNOTHERAPY OF CANCER
(2022)
Review
Chemistry, Multidisciplinary
Soraia Fernandes, Marco Cassani, Francesca Cavalieri, Giancarlo Forte, Frank Caruso
Summary: The application of lipid-based nanoparticles shows potential for cancer therapy, but its use in delivering drugs to solid tumors is limited. Instead, using lipid-based nanoparticles to remotely activate immune system responses is an emerging effective strategy. Overcoming challenges such as tumor heterogeneity and ineffective penetration of activated T cells within the tumor is necessary for the successful translation of this approach. Implementing advanced preclinical models, such as tumor organoids, will contribute to the development of innovative antitumor therapies.
Review
Oncology
Maria de Miguel, Pablo Umana, Ana Luiza Gomes de Morais, Victor Moreno, Emiliano Calvo
Summary: T-cell engagers (TCE) are a novel group of treatments that simultaneously engage T-cell surface molecules and tumoral cell antigens. Success has been observed in hematologic field but not yet in solid tumors due to their biological complexity. Research is ongoing to improve solid tumors therapeutics through different strategies.
CLINICAL CANCER RESEARCH
(2021)
Article
Multidisciplinary Sciences
Nicolas Cuburu, Lukasz Bialkowski, Sergio M. Pontejo, Shiv K. Sethi, Alexander T. F. Bell, Rina Kim, Cynthia D. Thompson, Douglas R. Lowy, John T. Schiller
Summary: Tumor infiltration by T cells plays a significant role in cancer progression and immunotherapy. This study explores the use of intratumoral injection of virus-derived peptide epitopes to activate preexisting antiviral T cell responses and promote antitumor responses or antigen spreading. The results show that this approach can act as a standalone therapy to control tumor growth and induce long-term antitumor immunity.
PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA
(2022)
Review
Immunology
Liangliang Meng, Yingtian Wei, Yueyong Xiao
Summary: Chemical ablation involves injecting chemical agents directly into solid tumors to kill cells and is currently used for palliative treatment. The effectiveness of different drugs has been clinically tested, but their diffusion and concentration limit their efficacy. Immunotherapy shows potential, but low patient response rates and immune-related adverse effects restrict its clinical applications. Intratumoral immunotherapy addresses these issues, but its efficacy alone is uncertain. This study focuses on the research of immunosuppressive tumor microenvironment with chemoablation and intratumoral immunotherapy, aiming to propose a new concept of intratumoral chemo-immunoablation that enhances the systemic anti-tumor immune response while reducing adverse drug effects.
FRONTIERS IN IMMUNOLOGY
(2023)
Article
Immunology
Suzanne van Duikeren, Marieke F. Fransen, Anke Redeker, Brigitte Wieles, Gerard Platenburg, Willem-Jan Krebber, Ferry Ossendorp, Cornelis J. M. Melief, Ramon Arens
JOURNAL OF IMMUNOLOGY
(2012)
Article
Cell Biology
B Wieles, J Pool, M Wilke, M Weber, HJ Kolb, RE Bontrop, E Goulmy
Article
Hematology
Bregje Mommaas, Astrid G. S. van Halteren, Jos Pool, Lars van der Veken, Brigitte Wieles, Mirjam H. M. Heemskerk, Els Goulmy
Article
Immunology
A Geluk, MR Klein, KLMC Franken, KE van Meijgaarden, B Wieles, KC Pereira, S Bührer-Sékula, PR Klatser, PJ Brennan, JS Spencer, DL Williams, MCV Pessolani, EP Sampaio, THM Ottenhoff
INFECTION AND IMMUNITY
(2005)
Article
Hematology
B Wieles, J Pool, R Derks, WJ Burlingham, E Goulmy
BIOLOGY OF BLOOD AND MARROW TRANSPLANTATION
(2005)
Article
Immunology
A Geluk, KE van Meijgaarden, KLMC Franken, YW Subronto, B Wieles, SM Arend, EP Sampaio, T de Boer, WR Faber, B Naafs, THM Ottenhoff
INFECTION AND IMMUNITY
(2002)
Article
Immunology
E Spierings, T de Boer, B Wieles, LB Adams, E Marani, THM Ottenhoff
JOURNAL OF IMMUNOLOGY
(2001)
Article
Immunology
A Macfarlane, R Mondragon-Gonzalez, F Vega-Lopez, B Wieles, J de Pena, O Rodriguez, RS de la Torre, RRP de Vries, THM Ottenhoff, HM Dockrell
CLINICAL AND DIAGNOSTIC LABORATORY IMMUNOLOGY
(2001)
Article
Immunology
A Geluk, KE van Meijgaarden, KLMC Franken, B Wieles, SM Arend, WR Faber, B Naafs, THM Ottenhoff
SCANDINAVIAN JOURNAL OF IMMUNOLOGY
(2004)